These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12536591)

  • 21. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
    Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
    Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
    Alexander EK; Larsen PR
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1073-7. PubMed ID: 11889166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic 131I dose in hyperthyroidism: role of pretreatment with thionamide.
    Kabadi U; Cech R
    Thyroidology; 1994 Dec; 6(3):87-92. PubMed ID: 7545000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjunctive treatment with propylthiouracil or iodine following radioiodine therapy for Graves' disease.
    Bazzi MN; Bagchi N
    Thyroid; 1993; 3(4):269-72. PubMed ID: 8118222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
    Tsai WC; Pei D; Wang TF; Wu DA; Li JC; Wei CL; Lee CH; Chen SP; Kuo SW
    Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism.
    Imseis RE; Vanmiddlesworth L; Massie JD; Bush AJ; Vanmiddlesworth NR
    J Clin Endocrinol Metab; 1998 Feb; 83(2):685-7. PubMed ID: 9467593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment outcome of Graves' disease in Thai children.
    Somnuke PH; Pusuwan P; Likitmaskul S; Santiprabhob J; Sawathiparnich P
    J Med Assoc Thai; 2007 Sep; 90(9):1815-20. PubMed ID: 17957924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
    El Refaei SM; Shawkat W
    Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies.
    Cooper DS
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3474-81. PubMed ID: 12915620
    [No Abstract]   [Full Text] [Related]  

  • 30. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
    Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
    N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of curative effect of 131I and antithyroid drugs in Graves' disease: a meta-analysis.
    Yuan J; Lu X; Yue Y
    Minerva Endocrinol; 2018 Dec; 43(4):511-516. PubMed ID: 28252265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioiodine therapy and thyrostatic drugs and iodine.
    Moka D; Dietlein M; Schicha H
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S486-91. PubMed ID: 12192550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and clinical significance of antineutrophil cytoplasmic antibody in Graves' patients treated with propylthiouracil.
    Cin MO; Gursoy A; Morris Y; Aydintug OT; Kamel N; Gullu S
    Int J Clin Pract; 2009 Feb; 63(2):299-302. PubMed ID: 19196368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease.
    Sridama V; McCormick M; Kaplan EL; Fauchet R; DeGroot LJ
    N Engl J Med; 1984 Aug; 311(7):426-32. PubMed ID: 6205272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of perinuclear antineutrophil cytoplasmic antibody in patients with Graves' disease treated with propylthiouracil or methimazole in Taiwan.
    Huang CN; Hsu TC; Chou HH; Tsay GJ
    J Formos Med Assoc; 2004 Apr; 103(4):274-9. PubMed ID: 15175822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucocorticoids do not influence the effect of radioiodine therapy in Graves' disease.
    Jensen BE; Bonnema SJ; Hegedüs L
    Eur J Endocrinol; 2005 Jul; 153(1):15-21. PubMed ID: 15994741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
    Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
    Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
    Chen JJ; Ladenson PW
    J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome of antithyroid medication and radioiodine therapy in pediatric Graves' disease.
    Leu SW; Chi CS; Shu SG
    Acta Paediatr Taiwan; 2003; 44(4):220-6. PubMed ID: 14674226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
    Urbannek V; Voth E; Moka D; Schicha H
    Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.